Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 15c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.93), $0.15 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $132 million versus the consensus estimate of $136.69 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of $725-750 million, versus the consensus of $653.5 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Blackstone to invest $30B in AI data centers in Japan over the next 3 to 5 years, says president and COO Jonathan Gray - Nikkei
• Doncasters Group IPO expected to price at top of range